Andreani1: Lateral Cord Stimulation as a New Treatment for Refractory Spastic Cerebral Palsy

Sponsor
Juan Carlos M. Andreani MD (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT02199015
Collaborator
Fundación CENIT (Other)
40
2
1
31
20
0.6

Study Details

Study Description

Brief Summary

The aim of our work is to investigate whether electrical Lateral Cord Stimulation (LCS) causes an inhibitory and modulatory action by indirect cerebellar activation, so releasing spasticity and the spastic syndrome in selected cases of patients with cerebral palsy

Condition or Disease Intervention/Treatment Phase
  • Device: Lateral spinal cord surgical implant of electrodes
N/A

Detailed Description

PROJECT Lateral Cord Stimulation was thought by the author to be employed in patients with spastic cerebral palsy with the aim to improve tonus, motor function and speech.

Nevertheless, as it has been demonstrated as acting on the basic phenomena related with spasticity, it's to say the propagated spinal responses, its use could be extended to other forms of spastic disease, like spastic limbs post stroke, brain congenital malformations producing spasticity and motor disorders as the main signs, post anoxic encephalopathy, etc.

In this preliminary clinical trial, classed as phase 3, our sample must be very limited to assure stable conditions for statistical significance, hence our group is going to be circumscribed to certain conditions and pathology.

In the future, as long the method could spread its use, the extension on indications in other pathological conditions is advisable thus, its possibilities of marketing could be enlarged with its use in a broader spectrum of spastic patients.

Calculated risks are similar to those related with the ancient surgical technique called "Scoville"technique, currently employed time ago for cervical discectomy (6) Investigational plan The purpose of this clinical trial is to release spasticity and by this means improve the condition of patients with spastic cerebral palsy by extradural lateral cord electrical stimulation, by using currently employed electrodes and neurostimulators Those devices are already FDA approved and currently used for Dorsal Column Stimulation with the objective to treat chronic Pain and spasticity (Spasmodic Torticollis).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Lateral Cord Electrical Stimulation Can Improve Spasticity in Chronic Spastic Cerebral Palsy
Anticipated Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Apr 1, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Spasticity, Cerebral Palsy

To perform a Lateral spinal cord surgical implant of electrodes for electrical neuromodulation of a cohort of selectyed patients with refractory Spastic Cerebral Palsy To compare spasticity and speech trouble´s evolution on a cohort of treated patients, by evaluating their pre and post operative status into one year follow up.

Device: Lateral spinal cord surgical implant of electrodes
The procedure is based on the classic approaches to posterior cervical region for herniated discs, actually not longer employed for that aim A unilateral hemilaminectomy will be performed at C3-C4 level, starting from 4th cervical spinous process. A multicontact electrode will be placed on the lateral surface of the spinal cord that will be subcutaneusly connected to an implanted pulse generator (IPG).
Other Names:
  • Implant of Neurostimulators (electrical generators)
  • Outcome Measures

    Primary Outcome Measures

    1. Ashworth Scale [Day 0 baseline evaluation. One post operative evaluation every 30 day during six months]

      The Ashworth scale has 5 points, they are: 1) no increase in muscle tone; 2) slight increase giving a catch when part is moved in flexion or extension; 3) more marked increase in tone but only after part is easily flexed; 4) considerable increase in tone; and 5) passive movement is difficult and affected part is rigid in flexion or extension

    Secondary Outcome Measures

    1. Barthel Index [Day 0 baseline evaluation. One post operative evaluation every 30 day during six months]

      The Barthel Index consists of 10 items that measure a person's daily functioning specifically the activities of daily living and mobility of the patient. The items include feeding, moving from wheelchair,etc, and the whole evaluation is from 100 maximum what means total independence, to 0, absolute dependence

    Other Outcome Measures

    1. Functional Independence Measure (FIM)- for speech [Day 0 baseline evaluation. One post operative evaluation every 30 day during six months]

      It is global independence assessment. In this case, we are going to take only those related to speech for disartria´s evaluation

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    16 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Aged sixteen or older

    • Spastic Cerebral Palsy with stable condition

    • Motor disability unilateral or predominantly unilateral.

    • Troubles of speech clinically evident.

    • Normal or Slightly sub-normal I.Q

    • No psychiatric disorders.

    Exclusion Criteria:
    • Severe cardiac or respiratory troubles

    • Fixed abnormal postures (except if previously corrected by orthopedic surgery)

    • Chronic recurrent bronchial or pulmonary infections

    • Chronic recurrent urinary infections

    • Severe osteoporosis on affected limbs

    • Chronic skin ulcerations.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Provincial Program of Neuromodulation La Plata Buenos Aires Argentina 1045
    2 Klinikummagdeburg Magdeburg Germany 399130

    Sponsors and Collaborators

    • Juan Carlos M. Andreani MD
    • Fundación CENIT

    Investigators

    • Study Director: Juan Carlos Andreani, MD, Sociedad Argentina de Neuromodulación
    • Principal Investigator: Werner Braunsdorf, MD, Klinik von Magdeburg - Germany

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Juan Carlos M. Andreani MD, MD, Sociedad Argenttina de Neuromodulación
    ClinicalTrials.gov Identifier:
    NCT02199015
    Other Study ID Numbers:
    • Andreani, JCM 1
    First Posted:
    Jul 24, 2014
    Last Update Posted:
    Sep 22, 2021
    Last Verified:
    Sep 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Juan Carlos M. Andreani MD, MD, Sociedad Argenttina de Neuromodulación
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 22, 2021